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signiﬁcantly in favor of early chest radiotherapy at 5 years (OR: 0.64, 
95% CI 0.44-0.92, P=0.02). Considering studies with an overall treat-
ment time of chest radiation of less than 30 days, the 5-year survival 
was even better (OR:0.56, 95%CI: 0.37-0.85; P = 0.006). As expected, 
esophageal, pulmonary and pulmonary toxicity was worse with initial 
concurrent chemoradiation but severe leukopenia was more frequent in 
patients receiving late chest radiotherapy (P = 0.0004). 
Although a conclusion in favor of early concurrent chemoradiation 
for LSCLC is not deﬁnitive, analysis of relevant subsets of the data 
is rational. Exclusion of non-platinum chemotherapy is supported by 
a meta-analysis showing superiority of SCLC regimens containing 
cisplatin and a conclusive phase III trial showing better survival of 
the EP regimen compared to a cyclophosphamide/anthracycline-based 
regimen.[7] Early thoracic irradiation cannot be expected to perform 
well unless it is coupled with a chemotherapy regimen compatible with 
concurrent radiotherapy and efﬁcacious enough to improve control of 
micro-metastases outside the thoracic irradiation volume. 
By evidence, the standard dose and treatment for LSCLC is 45 Gy 
delivered in three weeks in 30 fractions of 1.5 Gy, administered concur-
rently with cisplatin plus etoposide.[8] In Canada, 40 Gy in three weeks 
is still widely used.[9] We really do not know that longer treatments 
or higher doses are better for local control or survival, but we are now 
able to deliver doses up to 70 Gy in 7 weeks without a clear signal that 
higher doses are superior. 
Prophylactic Cranial Irradiation
Patients with cancer control outside the brain have a 60% actuarial risk 
of developing brain metastases within 2 to 3 years after starting treat-
ment. In a meta-analysis of 7 randomized trials evaluating the value of 
prophylactic cranial irradiation, the risk of developing central nervous 
system metastases was reduced by >50%.[10] Additionally, 3-year 
overall survival of complete responders (predominately LSCLC) was 
20.7% with PCI versus 15.3% in the control group. 
The selection of an optimal dose for PCI that would lead to further 
decreases in brain metastasis incidence with minimal toxicity is the 
subject of an ongoing international trial addressing the question of the 
optimal PCI dose for the prevention of metastases. A standard dose of 
25 Gy in 10 fractions is being compared to 36 Gy in 18 fractions or 36 
Gy in 24 twice daily fractions. PCI should not be given with systemic 
chemotherapy because of increased toxicity. 
Conclusion
Although small cell lung cancer (SCLC) makes up a smaller propor-
tion of all lung cancers than it did 25 years ago, it remains a common 
cause of cancer mortality that requires more clinical and basic research 
than is currently underway. Trials of newer chemotherapy variations 
have failed to produce a regimen that is clearly superior to the two drug 
combination of etoposide and cisplatin, which remains the standard of 
care for both limited and extensive stage SCLC. Paradoxically advanc-
es in this systemic disease have come from radiotherapy innovations 
for limited SCLC including addition of thoracic irradiation to systemic 
chemotherapy, more intense thoracic irradiation, early integration of 
thoracic irradiation with systemic chemotherapy and prophylactic 
cranial irradiation.[11] 
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In oncological patients with solid tumor, treatment is most often guided 
by histology and staging which are also the main eligibility criteria 
for clinical trials. However, it is known for decades that there might 
be considerable heterogeneity within the same histological type and 
that this heterogeneity leads to variations for response to treatment 
and survival with sensitivity to a given therapy being restricted to a 
subgroup of patients. If this heterogeneity is unknown and disregarded 
in the design of a clinical trial, it can have harmful consequences on the 
power of a trial to detect a beneﬁt for the investigational treatment, the 
loss of power depending on the differential treatment effect in sensitive 
and in non sensitive patients as well as on the true proportion of sen-
sitive patients, sensitive patients who are not necessarily accurately rep-
resented in phase II trials (1). Tumor biology might be responsible for 
the heterogeneity and progress in the knowledge of tumor biology did 
allow the development of molecularly targeted agents. This complicates 
drug development and, in particular, the design of randomised phase III 
clinical trials.
In some situations, at the time of initiating a phase III trial, we may be 
lacking from reliable and/or quick assays to select sensitive patients 
and, consequently, traditional trials with broad eligibility criteria are 
still used despite the fact that a true treatment effect on the sensitive 
patients only may be diluted by the absence of effect (or worse by a 
deleterious effect) in non sensitive patients. At the end of the trial, 
a stratiﬁed analysis can be done for the sensitivity status although a 
stratiﬁed randomisation for the sensitivity status might be wished to 
avoid random differences in the proportion of sensitive patients in both 
arms. Freidlin and Simon (2) proposed an attractive adaptive design 
combining in the same time the development of a classiﬁer and the 
conduct of a clinical trial for testing an overall effect of the investiga-
tional treatment and a speciﬁc effect in a subgroup of sensitive patients, 
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both tests being performed with an adequate power and control of the 
overall false positive error. When the rate of sensitive patients is low, 
this design reduces the chance of false rejection of an effective treat-
ment by the detection of an effect on a patients subgroup and when this 
rate is high, it does not affect much the probability of detecting the true 
overall effect.
Targeted designs are designs for whom the patients populations are en-
riched by a further selection criterion related to a marker. This marker, 
when positive, is supposed to be predictive for response to an inves-
tigational treatment and only patients with a positive marker will be 
eligible for a trial and those patients can be classically randomized be-
tween a control arm and the investigational, targeted for the presence of 
the marker, treatment. To be practically feasible, such a design requires 
that a reproducible method for assessing the marker does exist and can 
be applied quickly before randomizing a patient. Simon and Maito-
urnam (3) evaluated the efﬁciency of this design in terms of the gain 
of patients to be randomised and in terms of the gain of patients to be 
screened, according to various parameters : the proportion of sensitive 
patients and the accuracy of the method to select them, the response to 
the control arm, the differential effect of the investigational treatment in 
sensitive patients and in non sensitive patients compared to the control 
arm, the absolute improvement with the investigational treatment in 
sensitive patients. They showed that the reduction in the number of 
patients to be randomised can be very substantial in particular when the 
investigational treatment does not bring any beneﬁt for non sensitive 
patients, when there is an accurate method for identifying the sensitive 
patients (falsely identiﬁed sensitive patients will dilute treatment effect 
while falsely identiﬁed non sensitive patients will imply a higher num-
ber of patients to screen) and when the proportion of sensitive patients 
is low. In the situation, when there is no beneﬁt of the investigational 
treatment for non sensitive patients, the targeted design is also more 
efﬁcient than the untargeted design with regard to the required number 
of patients to screen.
A design where all patients are randomised, regardless of the positivity 
of the marker, can also be considered with a prospective assessment of 
that marker and a separate randomization procedure for sensitive and 
non sensitive patients. At the end of the trial, separate analyses can be 
conducted for the two subgroups or an interaction effect between treat-
ment and the sensitivity status may be looked at. Sample sizes required 
will depend on the type of analysis chosen (as well as on the proportion 
of sensitive patients and on the differential hypotheses formulated in 
the two strata) (4).
Other designs consider a strategy based on the sensitivity status (4). 
Once the status is known, patients are randomized to a strategy based 
on the marker of sensitivity or not based on the marker. One possibil-
ity is, in the strategy based on the sensitivity status, to treat with the 
investigational treatment patients expected to be sensitive while giving 
the control arm to the other patients. In the strategy not based on the 
marker, the control treatment is administered to all patients. This design 
however does not allow the assessment of the investigational treatment 
in the expected non sensitive patients as in one arm none of the patients 
receives the investigational treatment. It can then be modiﬁed to further 
randomize the patients allocated to the strategy not based on the marker 
between the control arm and the targeted therapy.
While in randomized phase III clinical trials, primary endpoint remains 
overall survival (or disease-free survival in some circumstances), 
the development of biological agents which may be cytostatic rather 
than cytotoxic may raise issues regarding the choice of the endpoint 
in phase II clinical trials, being classically response to treatment to 
take into account that the expected effect will rather be to slow or to 
stop the growth of the tumors rather than shrinking the lesions. More 
adequate endpoints may be stabilization rate or the rate of patients 
without progression at a particular time point (5). When these primary 
endpoints are considered, investigators may be faced with a lack of 
historical controls to formulate assumptions regarding acceptable and 
unacceptable rates of stabilisation or of patients without progression 
in addition to the problem that there might be no reliable assay for 
selecting patients susceptible to beneﬁt for the investigational treat-
ment. In such a situation, a design called randomized discontinuation 
design has been proposed by Rosner et al (6). All patients are initially 
given the drug. After a ﬁrst assessment, responding patients continue 
with the drug, treatment is stopped in progressing patients and patients 
with stabilisation are randomized between continuation with drug or 
continuation with a placebo with the expectation that the randomized 
patients population is a more homogeneous population of sensitive 
patients. The efﬁciency of this design has been studied by Freidlin and 
Simon (7) by comparing it to an upfront randomized design. They show 
that the degree of enrichment (ie the fraction of sensitive patients in the 
randomized part of the study) is the key factor for the success of the 
randomized discontinuation design.
Examples of trials having considered the described designs will be 
given in the context of the development of targeted agents for patients 
with lung cancer.
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Lung cancer is the most frequent cause of cancer deaths worldwide and 
its global incidence has been steadily increasing during recent decades. 
Surgery is the cornerstone of treatment in localized NSCLC but only 
20% of patients are considered surgical candidates at presentation. The 
vast majority of patients cannot be subjected to surgery either because 
of tumor advancement or poor medical condition. Patients with medi-
cally inoperable or locally advanced NSCLC are usually managed with 
radiotherapy, but only a few enjoy long-term survival. The limited 
efﬁcacy of single therapeutic modalities has led to the development of 
combination strategies, the subject of this presentation. 
